HIH News

First specific drug therapy for a severe early form of epilepsy

Epilepsy comes in a variety of forms. Those affected by a genetically determined variety have severe epileptic seizures as early as the first year of life. Until now, this form of epilepsy has been difficult to treat with the usual drugs. Researchers from Tübingen have now used a drug for the first time that is actually approved for the treatment of multiple sclerosis. It directly counteracts the underlying genetic defect and successfully alleviates the symptoms of the patients, reports the team led by Dr. Ulrike Hedrich-Klimosch, Dr. Stephan Lauxmann and Prof. Dr. Holger Lerche from the Hertie Institute for Clinical Brain Research, the University Hospital and the University of Tübingen.

See Press Release

Received the Eva Luise Köhler Research Prize for Rare Diseases 2018 for the project: Dr Ulrike Hedrich-Klimosch, Dr Markus Wolff, Dr Stephan Lauxmann, Dr Thomas Wuttke, Prof. Dr Hol-ger Lerche (from left to right).

Copyright: Kardinal | Hertie Institute for Clinical Brain Research (HIH)